Original Publication Date: 1 May, 2015
Publication / Source: Pharmacogenomics
Authors: Cristina Pérez-Ramírez, Marisa Cañadas-Garre, Enrique Jiménez-Varo et al.
Non-small-cell lung cancer (NSCLC) leads cancer-related deaths worldwide. Mutations in the kinase domain of the EGFR gene provide sensitivity to tyrosine kinase inhibitors (TKI) drugs. TKI show initial response rates over 75% in mutant EGFR-NSCLC patients, although most of these patients acquire resistance to EGFR inhibitors after therapy.